Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting

References

• de Boer-DennertMde WitRSchmitzPIPatient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonistsBr J Cancer1997768105510619376266
   PubMed Web of Science ®Google Scholar
• SunCCBodurkaDCWeaverCBRankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancerSupport Care Cancer200513421922715538640
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network [homepage on the Internet]NCCN Clinical Practice Guidelines in Oncology: Antiemesis Version 12016 Available from: www.nccn.orgAccessed December 28, 2016
   Google Scholar
• Bloechl-DaumBDeusonRRMavrosPHansenMHerrstedtJDelayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatmentJ Clin Oncol200624274472447816983116
   PubMed Web of Science ®Google Scholar
• HilariusDLKloegPHvan der WallEvan den HeuvelJJGundyCMAaronsonNKChemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based studySupport Care Cancer201220110711721258948
   PubMed Web of Science ®Google Scholar
• NavariRMThe safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomitingExpert Opin Drug Saf201615334335626699406
   PubMed Web of Science ®Google Scholar
• VidallCDielensegerPFarrellCEvidence-based management of chemotherapy-induced nausea and vomiting: a position statement from a European cancer nursing forumEcancermedicalscience2011521122276054
   PubMedGoogle Scholar
• SchwartzbergLHarrowBLalLSRadtchenkoJLymanGHResource utilization for chemotherapy-induced nausea and vomiting events in patients with solid tumors treated with antiemetic regimensAm Health Drug Benefits20158527328226380034
   PubMed Web of Science ®Google Scholar
• AaproMBlowerP5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?Cancer2005104111815929119
   PubMed Web of Science ®Google Scholar
• Garcia-RecioSGasconPBiological and pharmacological aspects of the NK1-receptorBiomed Res Int2015201549570426421291
   PubMed Web of Science ®Google Scholar
• ArmstrongDMPickelVMJohTHReisDJMillerRJImmunocytochemical localization of catecholamine synthesizing enzymes and neuropeptides in area postrema and medial nucleus tractus solitarius of rat brainJ Comp Neurol198119635055176163796
   PubMed Web of Science ®Google Scholar
• HeskethPJChemotherapy-induced nausea and vomitingN Engl J Med2008358232482249418525044
   PubMed Web of Science ®Google Scholar
• JordanKHinkeAGrotheyAA meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesisSupport Care Cancer20071591023103317205281
   PubMed Web of Science ®Google Scholar
• GrunbergSMDeusonRRMavrosPIncidence of chemotherapy-induced nausea and emesis after modern antiemeticsCancer2004100102261226815139073
   PubMed Web of Science ®Google Scholar
• HsiehRKChanAKimHKBaseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countriesSupport Care Cancer201523126327225120009
   PubMed Web of Science ®Google Scholar
• GrunbergSMAntiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysisAnn Oncol200718223324017108149
   PubMed Web of Science ®Google Scholar
• NavariRMGraySEKerrACOlanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trialJ Support Oncol20119518819522024310
   PubMedGoogle Scholar
• TanLLiuJLiuXClinical research of olanzapine for prevention of chemotherapy-induced nausea and vomitingJ Exp Clin Cancer Res20092813119775450
   PubMed Web of Science ®Google Scholar
• NavariRMQinRRuddyKJOlanzapine for the prevention of chemotherapy-induced nausea and vomitingN Engl J Med2016375213414227410922
   PubMed Web of Science ®Google Scholar
• RoilaFMolassiotisAHerrstedtJ2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patientsAnn Oncol201627Suppl 5v119v13327664248
   PubMed Web of Science ®Google Scholar
• HeskethPJBohlkeKLymanGHAntiemetics: American Society of Clinical Oncology focused guideline updateJ Clin Oncol201634438138626527784
   PubMed Web of Science ®Google Scholar
• DuffyRAMorganCNaylorRRolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferretsPharmacol Biochem Behav201210219510022497992
   PubMed Web of Science ®Google Scholar
• PomaAChristensenJDavisJKansraVMartellRHedleyMPhase 1 positron emission tomography (PET) study of the receptor occupancy of rolapitant, a novel NK-1 receptor antagonistJ Clin Oncol201432suppl Abstract e20690
   Google Scholar
• Van LaereKDe HoonJBormansGEquivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imagingClin Pharmacol Ther201292224325022739139
   PubMed Web of Science ®Google Scholar
• SpinelliTCalcagnileSGiulianoCNetupitant PET imaging and ADME studies in humansJ Clin Pharmacol20145419710824122871
   PubMed Web of Science ®Google Scholar
• Varubi® (rolapitant) [package insert]Waltham, MATesaro2015
   Google Scholar
• GanTJGuJSinglaNRolapitant for the prevention of postoperative nausea and vomiting: a prospective, double-blinded, placebo-controlled randomized trialAnesth Analg2011112480481221385988
   PubMed Web of Science ®Google Scholar
• Emend (fosaprepitant dimeglumine) for injection [package insert]Whitehouse, NJMerck Sharp & Dohme Corp2016
   Google Scholar
• Emend (aprepitant) [package insert]Whitehouse, NJMerck Sharp & Dohme Corp2015
   Google Scholar
• Akynzea® (netupitant and palonosetron) [package insert]Woodcliff Lake, NJEisai Inc2015
   Google Scholar
• PomaAChristensenJPertikisHAroraSHedleyMRolapitant and its major metabolite do not affect the pharmacokinetics of midazolam, a sensitive cytochrome P450 3A4 substrateSupport Care Cancer201321S154 Abstract 441
   Google Scholar
• WangXWangJKansraVPopulation pharmacokinetics of rolapitant in patients with chemotherapy-induced nausea and vomitingEuropean Cancer CongressVienna, AustriaSeptember 25–29, 2015 Poster 1588
   Google Scholar
• HeskethPJGrunbergSMGrallaRJThe oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – the Aprepitant Protocol 052 Study GroupJ Clin Oncol200321224112411914559886
   PubMed Web of Science ®Google Scholar
• Poli-BigelliSRodrigues-PereiraJCaridesADAddition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin AmericaCancer200397123090309812784346
   PubMed Web of Science ®Google Scholar
• RapoportBLJordanKBoiceJAAprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind studySupport Care Cancer201018442343119568773
   PubMed Web of Science ®Google Scholar
• NishimuraJSatohTFukunagaMCombination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trialEur J Cancer201551101274128225922233
   PubMed Web of Science ®Google Scholar
• GrunbergSChuaDMaruASingle-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol–EASEJ Clin Oncol201129111495150121383291
   PubMed Web of Science ®Google Scholar
• WeinsteinCJordanKGreenSASingle-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trialAnn Oncol201627117217826449391
   PubMed Web of Science ®Google Scholar
• HeskethPJRossiGRizziGEfficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal studyAnn Oncol20142571340134624608196
   PubMed Web of Science ®Google Scholar
• AaproMRugoHRossiGA randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapyAnn Oncol20142571328133324603643
   PubMed Web of Science ®Google Scholar
• RapoportBChuaDPomaAAroraSWangYFeinLEStudy of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC)Support Care Cancer201523113281328825940030
   PubMed Web of Science ®Google Scholar
• RapoportBLChasenMRGridelliCSafety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trialsLancet Oncol20151691079108926272769
   PubMed Web of Science ®Google Scholar
• SchwartzbergLSModianoMRRapoportBLSafety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trialLancet Oncol20151691071107826272768
   PubMed Web of Science ®Google Scholar
• HeskethPJSchnadigIDSchwartzbergLSEfficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapyCancer2016122152418242527176138
   PubMed Web of Science ®Google Scholar
• NavariRMAaproMAntiemetic prophylaxis for chemotherapy-induced nausea and vomitingN Engl J Med2016374141356136727050207
   PubMed Web of Science ®Google Scholar
• BarbourSWangXPomaAAroraSAaproMHerrstedtJLow risk of drug interactions with rolapitant is coadministered with CYP2S6 or BCRP substrates: integrated safety resultsEuropean Cancer CongressVienna, AustriaSeptember 25–29, 2015 Poster 1529
   Google Scholar
• RapoportBSchwartzbergLChasenMEfficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapyEur J Cancer201657233026851398
   PubMed Web of Science ®Google Scholar
• PalliSRGrabnerMQuimboRARugoHSThe impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomitingCancer Manag Res2015717518826124681
   PubMed Web of Science ®Google Scholar
• BurkeTAWisniewskiTErnstFRResource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital settingSupport Care Cancer201119113114020101417
   PubMed Web of Science ®Google Scholar
• GomezDRLiaoKPGiordanoSNguyenHSmithBDEltingLSAdherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer: a population-based studyCancer201311971428143623212885
   PubMed Web of Science ®Google Scholar
• EscobarYCajaravilleGVirizuelaJAIncidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) studySupport Care Cancer20152392833284026081597
   PubMed Web of Science ®Google Scholar
• MolassiotisASaundersMPValleJA prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centreSupport Care Cancer200816220120817926070
   PubMed Web of Science ®Google Scholar
• GrassiLBerardiMARuffilliFRole of psychosocial variables on chemotherapy-induced nausea and vomiting and health-related quality of life among cancer patients: a European studyPsychother Psychosom201584633934726402426
   PubMed Web of Science ®Google Scholar
• LindleyCMHirschJDO’NeillCVTransauMCGilbertCSOsterhausJTQuality of life consequences of chemotherapy-induced emesisQual Life Res1992153313401299465
   PubMedGoogle Scholar
• MartinARPearsonJDCaiBElmerMHorganKLindleyCAssessing the impact of chemotherapy-induced nausea and vomiting on patients’ daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recallSupport Care Cancer200311852252712827483
   PubMed Web of Science ®Google Scholar
• ChasenMUrbanLSchnadigIImpact of rolapitant on quality of life (QoL) in patients (pts) receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC)Poster presented at: 2015 ASCO Annual MeetingMay 29 – June 2, 2015Chicago, IL Abstract 9615
   Google Scholar
• ChasenMUrbanLSchnadigIRolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapySupport Care Cancer2017251859227557833
   PubMed Web of Science ®Google Scholar
• BaschEPrestrudAAHeskethPJAntiemetics: American Society of Clinical Oncology clinical practice guideline updateJ Clin Oncol201129314189419821947834
   PubMed Web of Science ®Google Scholar
• AaproMKarthausMSchwartzbergLPhase 3 study of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting during repeated moderately emetogenic chemotherapy (MEC) cyclesJ Clin Oncol201432suppl Abstract 9502
   Google Scholar